Potential Therapeutic Value of Interleukin 1b-targeted Strategies in Atherosclerotic Cardiovascular Disease

  1. Viana-Huete, Vanesa 1
  2. Fuster, José J. 1
  1. 1 Centro Nacional de Investigaciones Cardiovasculares Carlos III
    info

    Centro Nacional de Investigaciones Cardiovasculares Carlos III

    Madrid, España

    ROR https://ror.org/02qs1a797

Journal:
Revista Española de Cardiología (English Edition)

ISSN: 1885-5857

Year of publication: 2019

Volume: 72

Issue: 9

Pages: 760-766

Type: Article

DOI: 10.1016/J.REC.2019.03.006 GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Revista Española de Cardiología (English Edition)

Abstract

Clinical trials have unequivocally shown that cholesterol-lowering drugs decrease the risk of atherosclerotic cardiovascular disease in an exceptionally wide range of individuals. Yet, even when treated optimally according to current standards, many individuals still experience life-threatening ischemic events. Emerging experimental and clinical evidence strongly suggests that persistent inflammation is a major driver of this residual risk, which has opened the door to the application of anti-inflammatory drugs for cardiovascular disease prevention. Here, we review our current knowledge of the biology of interleukin-1β, a key regulator of inflammation in atherosclerotic plaque and the target of the first clinical trial to demonstrate that an anti-inflammatory drug can effectively reduce cardiovascular risk. We discuss the challenges faced by interleukin-1β inhibitors and other anti-inflammatory compounds in their translation to the clinical scenario, and identify other potential targets within this signaling pathway that hold promise in the cardiovascular setting.

Bibliographic References

  • Ross, (1999), N Engl J Med., 340, pp. 115, 10.1056/NEJM199901143400207
  • Ross, (1999), Am Heart J., 138, pp. S419, 10.1016/S0002-8703(99)70266-8
  • Ruparelia, (2017), Nat Rev Cardiol., 14, pp. 133, 10.1038/nrcardio.2016.185
  • Libby, (2013), Immunity., 38, pp. 1092, 10.1016/j.immuni.2013.06.009
  • Libby, (2012), Arterioscler Thromb Vasc Biol., 32, pp. 2045, 10.1161/ATVBAHA.108.179705
  • Ridker, (2000), Circulation., 101, pp. 1767, 10.1161/01.CIR.101.15.1767
  • Liuzzo, (1994), N Engl J Med., 331, pp. 417, 10.1056/NEJM199408183310701
  • (2013), Lancet., 382, pp. 769, 10.1016/S0140-6736(13)60900-9
  • Ridker, (2017), N Engl J Med., 377, pp. 1119, 10.1056/NEJMoa1707914
  • Libby, (2017), J Am Coll Cardiol., 70, pp. 2278, 10.1016/j.jacc.2017.09.028
  • Manson, (1989), Eur J Immunol., 19, pp. 261, 10.1002/eji.1830190207
  • Hiscott, (1993), Mol Cell Biol., 13, pp. 6231, 10.1128/MCB.13.10.6231
  • Warner, (1987), J Immunol., 139, pp. 1911
  • Dinarello, (1987), J Immunol., 139, pp. 1902
  • Warner, (1987), J Exp Med., 165, pp. 1316, 10.1084/jem.165.5.1316
  • Alexander, (2012), Physiol Genomics., 44, pp. 417, 10.1152/physiolgenomics.00160.2011
  • Ridker, (2016), Circ Res., 118, pp. 145, 10.1161/CIRCRESAHA.115.306656
  • Miller, (2011), Circ Res., 108, pp. 235, 10.1161/CIRCRESAHA.110.223875
  • Que, (2018), Nature., 558, pp. 301, 10.1038/s41586-018-0198-8
  • Paramel Varghese, (2016), J Am Heart Assoc., pp. 5
  • Rajamaki, (2010), PLoS One., 5, pp. e11765, 10.1371/journal.pone.0011765
  • Duewell, (2010), Nature., 464, pp. 1357, 10.1038/nature08938
  • Robblee, (2016), Cell Rep., 14, pp. 2611, 10.1016/j.celrep.2016.02.053
  • Sheedy, (2013), Nat Immunol., 14, pp. 812, 10.1038/ni.2639
  • Wen, (2011), Nat Immunol., 12, pp. 408, 10.1038/ni.2022
  • Palomo, (2015), Cytokine., 76, pp. 25, 10.1016/j.cyto.2015.06.017
  • Kirii, (2003), Arterioscler Thromb Vasc Biol., 23, pp. 656, 10.1161/01.ATV.0000064374.15232.C3
  • Isoda, (2004), Arterioscler Thromb Vasc Biol., 24, pp. 1068, 10.1161/01.ATV.0000127025.48140.a3
  • Shemesh, (2012), Atherosclerosis., 222, pp. 329, 10.1016/j.atherosclerosis.2011.12.010
  • Merhi-Soussi, (2005), Cardiovasc Res., 66, pp. 583, 10.1016/j.cardiores.2005.01.008
  • Chi, (2004), Circulation., 110, pp. 1678, 10.1161/01.CIR.0000142085.39015.31
  • Elhage, (1998), Circulation., 97, pp. 242, 10.1161/01.CIR.97.3.242
  • Nicklin, (2000), J Exp Med., 191, pp. 303, 10.1084/jem.191.2.303
  • Vromman, (2019), Eur Heart J., 10.1093/eurheartj/ehz008
  • Bhaskar, (2011), Atherosclerosis., 216, pp. 313, 10.1016/j.atherosclerosis.2011.02.026
  • Menu, (2011), Cell Death Dis., 2, pp. e137, 10.1038/cddis.2011.18
  • Gomez, (2018), Nat Med., 24, pp. 1418, 10.1038/s41591-018-0124-5
  • Ridker, (2011), Am Heart J., 162, pp. 597, 10.1016/j.ahj.2011.06.012
  • Kleemann, (2008), Cardiovasc Res., 79, pp. 360, 10.1093/cvr/cvn120
  • Hopkins, (2013), Physiol Rev., 93, pp. 1317, 10.1152/physrev.00004.2012
  • Galea, (1996), Arterioscler Thromb Vasc Biol., 16, pp. 1000, 10.1161/01.ATV.16.8.1000
  • Ridker, (2012), Circulation., 126, pp. 2739, 10.1161/CIRCULATIONAHA.112.122556
  • Strang, (2013), Atherosclerosis., 229, pp. 174, 10.1016/j.atherosclerosis.2013.04.031
  • Nishimoto, (2010), Mod Rheumatol., 20, pp. 222, 10.3109/s10165-010-0279-5
  • Gram, (2019), Pharmacol Res., 10.1016/j.phrs.2019.01.023
  • Everett, (2018), J Am Coll Cardiol., 71, pp. 2392, 10.1016/j.jacc.2018.03.002
  • Ridker, (2018), J Am Coll Cardiol., 71, pp. 2405, 10.1016/j.jacc.2018.03.490
  • Swirski, (2018), Nat Rev Cardiol., 15, pp. 79, 10.1038/nrcardio.2017.208
  • Weber, (2017), Circ Res., 121, pp. 1119, 10.1161/CIRCRESAHA.117.311984
  • Baylis, (2017), Arterioscler Thromb Vasc Biol., 37, pp. e174, 10.1161/ATVBAHA.117.310097
  • Hansson, (2017), Circulation., 136, pp. 1875, 10.1161/CIRCULATIONAHA.117.030484
  • Ibanez, (2017), Circ Res., 121, pp. 1320, 10.1161/CIRCRESAHA.117.312200
  • Crea, (2018), Circulation., 137, pp. 1100, 10.1161/CIRCULATIONAHA.117.032178
  • Verma, (2017), Cell Metab., 26, pp. 703, 10.1016/j.cmet.2017.09.022
  • Abbate, (2017), J Cardiovasc Pharmacol., 70, pp. 353, 10.1097/FJC.0000000000000546
  • Sehested, (2019), JAMA Cardiol., 10.1001/jamacardio.2018.4566
  • Ridker, (2018), Lancet., 391, pp. 319, 10.1016/S0140-6736(17)32814-3
  • Ridker, (2018), Eur Heart J., 39, pp. 3499, 10.1093/eurheartj/ehy310
  • Cardoso, (2018), Mayo Clin Proc., 93, pp. 830, 10.1016/j.mayocp.2018.04.003
  • European Medicines Agency. Canakinumab Novartis: Withdrawal of the marketing authorisation application. Available at: https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/canakinumab-novartis.
  • Fuster, (2018), Circ Res., 122, pp. 523, 10.1161/CIRCRESAHA.117.312115
  • Jaiswal, (2014), N Engl J Med., 371, pp. 2488, 10.1056/NEJMoa1408617
  • Jaiswal, (2017), N Engl J Med., 377, pp. 111, 10.1056/NEJMoa1701719
  • Fuster, (2017), Science., 355, pp. 842, 10.1126/science.aag1381
  • Svensson, (2018), Circulation., 138, pp. A15111
  • Ridker, (2017), Lancet., 390, pp. 1833, 10.1016/S0140-6736(17)32247-X
  • Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (Canopy-A). Available at: https://clinicaltrials.gov/ct2/show/NCT03447769.
  • Everett, (2018), Circulation.
  • Harouki, (2017), JACC Basic Transl Sci., 2, pp. 418, 10.1016/j.jacbts.2017.06.005
  • Toldo, (2014), J Cardiovasc Pharmacol., 64, pp. 1, 10.1097/FJC.0000000000000106
  • Sano, (2018), J Am Coll Cardiol., 71, pp. 875, 10.1016/j.jacc.2017.12.037
  • Dorsheimer, (2019), JAMA Cardiol., 4, pp. 25, 10.1001/jamacardio.2018.3965
  • Toldo, (2013), Exp Physiol., 98, pp. 734, 10.1113/expphysiol.2012.069831
  • Van Tassell, (2010), J Cardiovasc Pharmacol., 55, pp. 117, 10.1097/FJC.0b013e3181c87e53
  • Sager, (2015), Circulation., 132, pp. 1880, 10.1161/CIRCULATIONAHA.115.016160
  • Abbate, (2010), Eur J Heart Fail., 12, pp. 319, 10.1093/eurjhf/hfq017
  • Liberale, (2018), Eur Heart J., 39, pp. 3511, 10.1093/eurheartj/ehy286
  • Mangan, (2018), Nat Rev Drug Discov., 17, pp. 588, 10.1038/nrd.2018.97
  • Coll, (2015), Nat Med., 21, pp. 248, 10.1038/nm.3806
  • Van der Heijden, (2017), Arterioscler Thromb Vasc Biol., 37, pp. 1457, 10.1161/ATVBAHA.117.309575
  • Van Hout, (2017), Eur Heart J., 38, pp. 828
  • O’Neill, (2018), N Engl J Med., 378, pp. 198
  • LaRock, (2016), Sci Immunol., pp. 1
  • Mauer, (2015), Trends Immunol., 36, pp. 92, 10.1016/j.it.2014.12.008
  • Fuster, (2014), EMBO J., 33, pp. 1425, 10.15252/embj.201488856
  • Pal, (2014), Immunol Cell Biol., 92, pp. 331, 10.1038/icb.2014.16
  • Kleveland, (2016), Eur Heart J., 37, pp. 2406, 10.1093/eurheartj/ehw171
  • ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial (ASSAIL-MI). Available at: https://clinicaltrials.gov/ct2/show/NCT03004703.